Inhibikase Therapeutics (IKT) Profit After Tax Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 111.59% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -19.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.75% |
| Dec 31, 2025 | -4.96% |
| Sep 30, 2025 | -106.48% |
| Jun 30, 2025 | -99.93% |
| Mar 31, 2025 | -194.19% |
| Dec 31, 2024 | -190.40% |
| Sep 30, 2024 | -25.74% |
| Jun 30, 2024 | 14.16% |
| Mar 31, 2024 | -3.84% |
| Dec 31, 2023 | 2.36% |
| Sep 30, 2023 | -2.24% |
| Jun 30, 2023 | -24.53% |
| Mar 31, 2023 | 3.51% |
| Dec 31, 2022 | 15.13% |
| Sep 30, 2022 | -0.52% |
| Jun 30, 2022 | -76.01% |
| Mar 31, 2022 | -75.98% |
| Dec 31, 2021 | -317.36% |
| Sep 30, 2021 | -566.75% |
| Jun 30, 2021 | -524.88% |